Curr Drug Metab. 2020 Aug 20. doi: 10.2174/1389200221999200820163337. Online ahead of print.
BACKGROUND: Among all cancers, lung cancer has high mortality among patients in most of countries in the world. Targeting delivery of anticancer drugs can significantly reduce the side effects and dramatically improve the treating effect. Folate, which is one suitable ligand, can be modified to the surface of tumor-selective drug delivery systems. Because it can selectively bind to the folate receptor, which is highly expressed on the surfaces of lung tumor cells.
OBJECTIVE: This study aimed to construct a kind of folate-targeted topotecan liposomes for investigating its efficacy and mechanism of action in the treatment of lung cancer in preclinical models.
METHODS: We conjugated topotecan liposomes with folate, and the liposomes were characterized by particle size, entrapment efficiency, cytotoxicity to A549 cells and in vitro release profile. Technical evaluations were performed on lung cancer A549 cells and xenografted A549 cancer cells in female nude mice, and the pharmacokinetics of the drug were evaluated in female SD rats.
RESULTS: The folate-targeted topotecan liposomes were proven to show effectiveness in targeting lung tumors. The antitumor effects of these liposomes were demonstrated by the decreased tumor volume and improved therapeutic efficacy. The folate-targeted topotecan liposomes also lengthened the topotecan blood circulation time.
CONCLUSION: The folate-targeted topotecan liposomes are effective drug delivery systems and can be easily modified with folate, enabling the targeted liposomes to deliver topotecan to lung cancer cells and kill them, which could be used as potential carriers for lung chemotherapy.